First-in-human trial of Gd-based theranostic nanoparticles: MRI assessment of uptake and biodistribution in patients with multiple brain metastases - Université Grenoble Alpes Accéder directement au contenu
Communication Dans Un Congrès Année : 2019

First-in-human trial of Gd-based theranostic nanoparticles: MRI assessment of uptake and biodistribution in patients with multiple brain metastases

Résumé

We report here the main MRI findings of a dose escalation phase 1 clinical trial with intravenous administration of theranostic AGuIX nanoparticles, conducted in 15 patients with brain metastases with the objective of evaluating the efficacy of the nanoparticles as contrast agent and radiosensitizer for brain metastases. The nanoparticles were found to enhance four different histological types of brain metastases up to one week after nanoparticle administration. Quantitative measurements of nanoparticle concentration in all types of brain metastases were obtained two hours after administration to patient - and incidentally two hours before the first session of whole brain radiotherapy.
Fichier non déposé

Dates et versions

hal-03356567 , version 1 (28-09-2021)

Identifiants

  • HAL Id : hal-03356567 , version 1

Citer

Sandrine Dufort, Camille Verry, Benjamin Lemasson, Sylvie Grand, Yannick Crémillieux, et al.. First-in-human trial of Gd-based theranostic nanoparticles: MRI assessment of uptake and biodistribution in patients with multiple brain metastases. ISMRM 27th Annual Meeting & Exhibition, May 2019, Montréal, Canada. ⟨hal-03356567⟩
28 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More